Mazdutide

Summary

Mazdutide (CHEMBL5095358) is a phase-3 clinical-stage protein targeting GLP1R and GCGR; indicated across 5 conditions including type 2 diabetes mellitus and obesity disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 2 (GLP1R, GCGR)
• Indications: 5 conditions
• Clinical trials: 30

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095358
Name	Mazdutide
Type	Protein
Max phase	3

Also known as: Ibi-362, Ibi362, LY-3305677, LY3305677, Mazdutida, Mazdutide, MAZDUTIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GLP1R	GLP-1 receptor	Agonist	7.64	0.2%	P43220
GCGR	glucagon receptor	Agonist	7.84	0.2%	P47871

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): GLP1R, GCGR.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	2	GCGR, GLP1R
Glucagon-type ligand receptors	2	GCGR, GLP1R
Glucagon signaling in metabolic regulation	1	GCGR
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	1	GLP1R
G alpha (q) signalling events	1	GCGR

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
cellular response to glucagon stimulus	2
activation of adenylate cyclase activity	1
positive regulation of cytosolic calcium ion concentration	1
learning or memory	1
regulation of heart contraction	1
post-translational protein targeting to membrane, translocation	1
negative regulation of blood pressure	1
positive regulation of blood pressure	1
hormone secretion	1
response to psychosocial stress	1
regulation of biological quality	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
obesity disorder	3	MONDO:0011122	EFO:0001073
diabetes mellitus	1	MONDO:0005015	EFO:0000400
kidney disorder	1	MONDO:0005240	EFO:0003086
metabolic dysfunction-associated steatotic liver disease	1	MONDO:0013209	EFO:0003095

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE3	11
PHASE2	7
PHASE1	7
PHASE1/PHASE2	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06164873	PHASE3	ACTIVE_NOT_RECRUITING	A Study of IBI362 9 mg in Chinese Adults With Obesity
NCT06184568	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
NCT06884293	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT06931028	PHASE3	RECRUITING	A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
NCT07083154	PHASE3	RECRUITING	GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
NCT07255209	PHASE3	RECRUITING	A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07417306	PHASE3	NOT_YET_RECRUITING	A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
NCT07469800	PHASE3	RECRUITING	Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
NCT05606913	PHASE3	COMPLETED	A Study of IBI362 in Participants With Type 2 Diabetes
NCT05607680	PHASE3	COMPLETED	A Study of IBI362 in Participants With Obesity or Overweight
NCT05628311	PHASE3	COMPLETED	A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
NCT06143956	PHASE2	RECRUITING	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06519656	PHASE1/PHASE2	RECRUITING	Efficacy of Mazdutide for Treating PCOS
NCT06817356	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
NCT06862908	PHASE2	RECRUITING	A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06937749	PHASE2	RECRUITING	A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07000955	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
NCT04440345	PHASE1/PHASE2	COMPLETED	Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
NCT04466904	PHASE1/PHASE2	COMPLETED	Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
NCT04904913	PHASE2	COMPLETED	A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT04965506	PHASE2	COMPLETED	A Study of IBI362 in Chinese Patients With Type 2 Diabetes
NCT06124807	PHASE2	COMPLETED	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT02972645	PHASE1	COMPLETED	A Study of LY3305677 in Healthy Participants
NCT03325387	PHASE1	COMPLETED	A Study of Multiple Doses of LY3305677 in Healthy Participants
NCT03928379	PHASE1	COMPLETED	A Study of LY3305677 in Participants With Type 2 Diabetes
NCT05623839	PHASE1	COMPLETED	A Study of LY3305677 in Participants With Obesity Or Overweight
NCT05793450	PHASE1	COMPLETED	Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
NCT05815680	PHASE1	COMPLETED	A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
NCT06536023	PHASE1	COMPLETED	This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
NCT07517042	Not specified	RECRUITING	ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

41 molecules share ≥1 primary target. Top 41 by shared-target count:

Molecule	Source	Status	Shared targets
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	GCGR, GLP1R
GLUCAGON	ChEMBL	Phase 4 (approved)	GCGR, GLP1R
COTADUTIDE	ChEMBL	Phase 2	GCGR, GLP1R
PF-06291874	ChEMBL	Phase 2	GCGR, GLP1R
LIRAGLUTIDE	ChEMBL + PubChem	Phase 4 (approved)	GLP1R
ELAGOLIX	ChEMBL	Phase 4 (approved)	GLP1R
EXENATIDE	ChEMBL	Phase 4 (approved)	GLP1R
LOPERAMIDE	ChEMBL	Phase 4 (approved)	GLP1R
PERPHENAZINE	ChEMBL	Phase 4 (approved)	GLP1R
SECRETIN	ChEMBL	Phase 4 (approved)	GLP1R
SEMAGLUTIDE	ChEMBL	Phase 4 (approved)	GLP1R
TIRZEPATIDE	ChEMBL	Phase 4 (approved)	GLP1R
TOLVAPTAN	ChEMBL	Phase 4 (approved)	GLP1R
ORFORGLIPRON	ChEMBL	Phase 3	GLP1R
ADOMEGLIVANT	ChEMBL	Phase 2	GCGR
DANUGLIPRON	ChEMBL	Phase 2	GLP1R
DEVAZEPIDE	ChEMBL	Phase 2	GLP1R
GLP-1	ChEMBL	Phase 2	GLP1R
LOTIGLIPRON	ChEMBL	Phase 2	GLP1R
MK-0893	ChEMBL	Phase 2	GCGR
MK-3577	ChEMBL	Phase 2	GCGR
Aclidinium Bromide	PubChem	Approved	GCGR
Acyclovir	PubChem	Approved	GCGR
Allopurinol	PubChem	Approved	GCGR
Alogliptin	PubChem	Approved	GCGR
Bosentan	PubChem	Approved	GCGR
Clozapine	PubChem	Approved	GCGR
Crizotinib	PubChem	Approved	GCGR
Desloratadine	PubChem	Approved	GCGR
Ethambutol	PubChem	Approved	GCGR
Fidaxomicin	PubChem	Approved	GCGR
Methotrexate	PubChem	Approved	GCGR
Olanzapine	PubChem	Approved	GCGR
Olmesartan Medoxomil	PubChem	Approved	GCGR
Propoxyphene	PubChem	Approved	GCGR
Pyrazinamide	PubChem	Approved	GCGR
rifampin	PubChem	Approved	GCGR
Sildenafil	PubChem	Approved	GCGR
Tegaserod	PubChem	Approved	GCGR
Tiotropium Bromide Monohydrate	PubChem	Approved	GCGR
Valacyclovir	PubChem	Approved	GCGR